Latest news with #HansaBiopharma
Yahoo
7 days ago
- Business
- Yahoo
Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025
LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS) on Monday, June 16, 2025 at 14:00 CEST / 8:00 AM EDT. Pre-registration is required and can be found at this link. Presentations by Dr. David R. Cornblath, MD, Johns Hopkins University School of Medicine and Dr. Simon Rinaldi MRCP (Neuro), PhD, University of Oxford will discuss the unmet need and current treatment landscape for GBS, an acute, rare, paralyzing inflammatory disease of the peripheral nervous system, as well as the role of Immunoglobulin G (IgG) in GBS and recent advancements in science and research. Company management including Hitto Kaufmann, Chief R&D Officer, and Elisabeth Sonesson, VP, Global Franchise Lead Autoimmunity, will highlight current activities and anticipated milestones for the Company in the autoimmune space. A live Q&A will follow the presentations. This is the first in a series of Science Deep Dive virtual events specifically aimed for the investor community and focusing on Hansa's disease areas - Autoimmune, Gene Therapy, and Kidney Transplantation. About David R. Cornblath, MD Dr. David Cornblath received his medical degree from Case Western Reserve University, completed an internship at University Hospitals in Cleveland, Ohio, and neurology residency at the Hospital of the University of Pennsylvania. He served as Clinical Fellow of the Muscular Dystrophy Association at the Peripheral Nerve Morphology Laboratory and then joined the Faculty at Johns Hopkins, rising to rank of Professor and serving as Director of the Neurology EMG Laboratory. Currently retired, Dr. Cornblath continues to consult, serving on safety monitoring boards and clinical trial development programs. He also holds the title of Professor Emeritus of Neurology at Johns Hopkins. About Simon Rinaldi, MRCP(Neuro), PhD Dr. Simon Rinaldi is a clinician scientist and clinical neurologist who leads the University of Oxford's programme of inflammatory neuropathy research. This research spans from in vitro disease modelling using cell-based assays to biomarker discovery, clinical phenotyping, and clinical trials. His lab has developed models of immune mediated axonal injury and demyelination using human induced pluripotent stem cell derived myelinating co-cultures. These experimental systems are now being used to learn more about the mechanisms of immune-mediated peripheral nerve injury, and are a valuable tool in the search for novel auto-antibodies and for the discovery and pre-clinical evaluation of fluid biomarkers. The lab also runs the only UK based diagnostic testing service for nodal and paranodal antibodies, which associate with distinct forms of autoimmune nodopathy, and the underlying B-cell biology of these and related peripheral nerve disorders is a more recent area of study. His research programme also includes a clinical / observational study of chronic inflammatory neuropathy (Bio-SPiN). The group additionally contributes to and benefits from close links with the comprehensive and high-quality clinical-serological database of 2000 patients encapsulated in the International GBS Outcome Study (IGOS) and has been involved in therapeutic trials in Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and multifocal motor neuropathy (MMN). Conference call details To register and to submit questions in advance, please use the following link: To participate in the telephone conference, please use the dial-in details provided below: Participant Dial In (Toll Free): 1-833-821-3542 Participant International Dial In: 1-412-652-1248 The webcast will be available on: Contacts for more information: Evan Ballantyne, Chief Financial OfficerIR@ Stephanie Kenney, VP Global Corporate Affairsmedia@ Notes to editors About Hansa Biopharma Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at and follow us on LinkedIn. ©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved. This information was brought to you by Cision The following files are available for download: 250609 - HNSA Autoimmune Deep Dive 16 June 2025 View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
13-05-2025
- Business
- Business Upturn
Eleva Appoints Donato Spota as Chief Financial Officer
By GlobeNewswire Published on May 13, 2025, 11:30 IST Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions. Danielle Püschel, currently serving as CFO, is appointed as Chief Accounting Officer. 'Eleva continues to strengthen its leadership team in line with the growing maturity of our proprietary development activities and steady progress in commercializing our technology platform. It is a pleasure to welcome Donato, whose proven experience in financial management of rapidly growing companies, makes him the ideal candidate to help us successfully navigate the ongoing transformation of Eleva,' commented Björn Cochlovius, Ph.D., Chief Executive Officer and Managing Director of Eleva. 'I also want to express my special thanks to Danielle Püschel for her commitment and leadership over the last 16 years at Eleva. The entire team is glad Danielle will continue her career with the company.' Mr. Spota is a senior executive with more than 25 years of international pharmaceutical industry experience. In his previous position as CFO of Hansa Biopharma, a Nasdaq Stockholm-listed biopharmaceutical company, he supported the progress of Hansa Biopharma's R&D pipeline and its transformation to a commercial-stage company by contributing to the corporate business and financial strategy and securing growth financing in excess of USD 200 million. Prior to joining Hansa Biopharma, Mr. Spota was CFO at Basilea Pharmaceutica AG, a Swiss-listed biopharmaceutical company. Mr. Spota held other senior financial leadership positions, including Global Head of Finance & Services and Head of Global Controlling at Basilea. Mr. Spota holds a degree in Information Technology and an in Business Administration from the HfWU University Nürtingen-Geislingen, Germany. Donato Spota added: 'Eleva is accelerating and expanding both of its core business activities in proprietary drug development and high-value product partnerships based on our transformative technology platform. I'm looking forward to working closely with Björn and the leadership team to help refine and successfully execute Eleva's growth strategy for both strategic pillars of this exciting business.' ABOUT ELEVA Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biologics based on a breakthrough moss-based technology platform. The company's proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. Dry AMD has been selected as the second indication. The company's aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programs are sourced from Eleva's transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with tremendous therapeutic potential. MEDIA CONTACTS INVESTOR CONTACT Attachments 13MAY2025_Eleva_CFO_Appointment_ENG_FINAL Donato Spota Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
13-05-2025
- Business
- Yahoo
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
LUND, Sweden, May 13, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President U.S. effective 19 May. Ms Törnsén will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee. Maria Törnsén has more than 20 years experience across global and US operations, where she held multiple senior commercial leadership roles. Most recently, she held the position of President North America at Calliditas Therapeutics, where she was responsible for the US commercial and medical affairs organization, until it was acquired by Asahi Kasei Corporation of Japan in September 2024. Previously Ms Törnsén held senior leadership and commercial leadership roles at Sarepta Therapeutics (SVP, US General Manager), Sanofi Genzyme (VP, Global Thereapeutic Area Head) and Shire plc (VP, Head of Sales and Marketing). During her career she has launched multiple products in the US and led a $1.6Bn global franchise. Ms Törnsén is a member of the board of directors of Immunic Therapeutics and has a Master of Science (MSc) in International Business Administration from Lund University, Sweden. "We are pleased to welcome Ms Törnsén to the executive management team as COO and President of the US business. She brings invaluable experience in the area of rare diseases and gene therapy, from building commercial organizations, launching new products and driving growth and profitability, which will be critical as we prepare for the next phase of our development," said CEO Renée Aguiar-Lucander. "I am delighted to join Hansa at this exciting time in the company's history. I look forward to working with the Hansa team and leveraging my experience from prior roles, to support the continued growth of IDEFIRIX and prepare for multiple anticipated catalysts in the second half of 2025," said Maria Törnsén. Contacts for more information:Evan Ballantyne, Chief Financial OfficerIR@ Kenney, VP Global Corporate Affairsmedia@ Notes to editors About Hansa Biopharma Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at and follow us on LinkedIn. ©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved. This information was brought to you by Cision The following files are available for download: 250513-HNSA COO US president_ENG View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
